In brief
Federal officials have given the go-ahead for Evita Solutions to market a generic version of mifepristone, an abortion pill effective up to 10 weeks into pregnancy. This decision has faced significant opposition from anti-abortion groups, especially aligned with the Trump administration, who claim it reflects bureaucratic overreach. The FDA, guided by current and previous administrations, has consistently deemed mifepristone safe since its original approval in 2000, while the new approval comes against a backdrop of heightened scrutiny and pressure from abortion opponents.
Federal officials have approved another generic version of the abortion pill mifepristone, leading to immediate pushback from anti-abortion groups linked to the Trump administration. Evita Solutions, the drugmaker, has announced on its website that the Food and Drug Administration (FDA) has signed off on its low-cost formulation of the pill, which is known to terminate pregnancies up to 10 weeks. The approval has been condemned by Students for Life Action, which labeled it a 'stain on the Trump presidency' and demanded a re-evaluation of the drug's safety. This criticism is significant as Trump’s former health officials, including Health Secretary Robert F. Kennedy Jr., are under pressure from anti-abortion advocates to reassess mifepristone’s approval. Since its introduction in 2000, mifepristone has been consistently classified as safe by FDA scientists. In light of ongoing debates, Kennedy and FDA Commissioner Dr. Marty Makary have pledged to review the drug's safety extensively. The original FDA approval allowed for gradual easing of access, leading to the approval of the first generic pill by GenBioPro in 2019. A recent shift under President Biden allowed for online prescribing and mail-order delivery of mifepristone, further expanding access, much to the chagrin of anti-abortion groups. Despite the approval of this second generic, it is uncertain how it will influence the accessibility of the drug nationwide, with many states imposing restrictions that conflict with FDA guidelines.
